Clinical Scorecard: Impact of Age and Associated Comorbidities on Survival Outcomes in Patients with Advanced Breast Cancer Treated with Palbociclib, Ribociclib, and Abemaciclib: A Nationwide Retrospective Analysis

At a Glance

Key Highlights

• Hormone-receptor positive breast cancer accounts for 60%-65% of cases.
• CDK inhibitors have transformed the management of advanced breast cancer.
• Older adults are underrepresented in clinical trials for cancer treatments.
• Comorbidities in older patients may impact treatment tolerance and outcomes.
• Real-world data suggest older women with breast cancer have worse survival rates.

Guideline-Based Recommendations

Diagnosis

• Use ICD-10 for breast cancer diagnosis.

Management

• CDK inhibitors are considered standard care for advanced hormone-receptor positive breast cancer.

Monitoring & Follow-up

• Assess comorbidities and treatment tolerance regularly in older patients.

Risks

• Older patients may experience worse survival outcomes due to comorbidities.

Patient & Prescribing Data

Patients aged 18 years and older diagnosed with breast cancer.

Data on drug exposure and comorbidities were collected from national registers.

Clinical Best Practices

• Incorporate comprehensive geriatric assessments in treatment planning for older adults.
• Consider the impact of comorbidities on treatment choices and outcomes.

Related Resources & Content

• Finnish Cancer Registry
• International Classification of Diseases (ICD)